Core Insights - Slide Insurance Holdings, Inc. reported a strong second quarter for 2025, achieving significant year-over-year growth across key financial metrics, including gross premiums written, net income, and combined ratio [1][3][9]. Financial Performance - Gross premiums written increased by 25.0% year-over-year to $435.4 million, up from $348.3 million in the prior-year period, driven by the acquisition of additional policies and consistent renewal rates [4][9]. - Net income grew by 30.5% year-over-year to $70.1 million, compared to $53.7 million in the prior-year period, with diluted earnings per share at $0.56 [1][11][9]. - Total revenue rose by 25.1% to $261.6 million, compared to $209.1 million in the prior-year period, primarily due to increased net premiums earned [6][9]. Underwriting and Loss Ratios - The combined ratio improved by 250 basis points year-over-year to 67.4%, compared to 69.9% in the prior-year period, indicating better underwriting performance [1][10][9]. - The loss ratio improved by 850 basis points to 37.4%, down from 45.9% in the prior-year period, reflecting effective management of losses and expenses [7][9]. Operational Metrics - Policies in force as of June 30, 2025, totaled 348,439, an increase from 275,178 as of June 30, 2024, indicating strong growth in policy renewals and acquisitions [5][26]. - Policy acquisition and other underwriting expenses increased to $32.1 million from $17.8 million in the prior-year period, attributed to a higher number of policies in force [8][10]. Capital and Shareholder Value - The company completed its initial public offering in June 2025, which contributed to the growth in equity and overall financial strength [1][3]. - Return on equity for the quarter was 10.0%, down from 16.9% in the prior-year period, influenced by the increase in equity due to retained earnings and IPO proceeds [11][9]. Technology and Strategy - The company leverages advanced underwriting technology and a well-capitalized balance sheet to enhance its growth strategy and create long-term shareholder value [3][18].

-- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-- -- Remain on track to submit NAUTILUS data to FDA for potential IGE indication expansion in the second half of 2025— --CMS maintains current MS-DRG assignment for RNS System® procedures-- MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused ...

Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the PiNACLE pivotal trial of LYL314 in patients with large B-cell lymphoma receiving treatment in the third‑ or later-line (3L+) setting; remain on track to initiate a pivotal trial in the second-line (2L) setting by early 2026Entered into a securities purchase agreement for a private placement for gross proceeds of up t ...

- Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification; Final Analysis Anticipated by Year-end 2025 –- Reported Positive Phase 2 Results of SLS009 in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) with Trial Meeting All Primary Endpoints; Full Data Presentation Expected Later This Year -- Alignment with FDA to Advance SLS009 in a First-Line AML Trial with Enrollment Anticipated by Q1 2026 -- $25.3 million in Cash and Cash Equivalent ...

Q2 Revenue of $28.1 Million, up 13% Year-over-Year;Net Loss of $7.7 Million, an Improvement of $9.0 Million;Adjusted EBITDA of $3.5 Million, an Improvement of $6.4 Million LOS ANGELES, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Playboy, Inc. (NASDAQ: PLBY) (the “Company” or “Playboy”), one of the most recognizable and iconic lifestyle brands in the world, today announced financial and operational results for its second fiscal quarter ended June 30, 2025. Comments from Ben Kohn, Chief Executive Officer and President ...

Core Insights - Terex Corporation has completed a re-pricing of its term loan, which is expected to reduce cash interest costs by approximately $3 million annually [1] - The new term loan rate is set at S+175bps, improving by 25bps from the previous rate [2] Company Overview - Terex Corporation is a global industrial equipment manufacturer specializing in materials processing machinery, waste and recycling solutions, mobile elevating work platforms (MEWPs), and equipment for the electric utility industry [2] - The company designs, builds, and supports products used across various sectors including maintenance, manufacturing, energy, minerals and materials management, construction, waste and recycling, and the entertainment industry [2] - Terex provides lifecycle support through a global parts and services organization and offers digital solutions to maximize customer investment returns [2] - The company focuses on environmentally friendly products, including electric and hybrid offerings that provide quiet and emission-free performance, as well as products that support renewable energy and aid in waste recovery [2] - Terex products are manufactured in North America, Europe, and Asia Pacific, and are sold worldwide [2]

Core Insights - Zevra Therapeutics reported Q2 2025 net revenue of $25.9 million, significantly up from $4.4 million in Q2 2024, driven primarily by product net revenue of $21.8 million from MIPLYFFA [1][8] - The company completed the sale of its Pediatric Rare Disease Priority Review Voucher (PRV) for $150 million, enhancing its balance sheet as it advances commercial launches and development programs [1][5] - Zevra submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for arimoclomol, aimed at treating Niemann-Pick Disease Type C [1][7] Commercial Highlights - MIPLYFFA achieved 7 prescription enrollments in Q2 2025, totaling 129 since its launch, with market access reaching 52% of covered lives [7] - OLPRUVA saw 1 prescription enrollment in Q2 2025, bringing the total to 29, with market access increasing to 79% of covered lives [7] Financial Highlights - Total revenue for Q2 2025 was $25.9 million, including $21.5 million from MIPLYFFA, $0.3 million from OLPRUVA, and $2.6 million in net reimbursements for arimoclomol [8] - Operating expenses were $24.2 million, with R&D expenses decreasing to $3.4 million, while SG&A expenses increased to $20.8 million [14] - The company reported a net income of $74.7 million for Q2 2025, compared to a net loss of $19.9 million in Q2 2024 [10][14] Pipeline and Innovation Highlights - Arimoclomol has been designated as an Orphan Medicinal Product by the EMA, and the company is on track with its guidance for submission in the second half of 2025 [7][17] - Zevra enrolled 7 patients in the Phase 3 DiSCOVER trial of celiprolol for Vascular Ehlers-Danlos Syndrome during Q2 2025, totaling 39 enrolled patients [7] Corporate Highlights - As of June 30, 2025, Zevra's cash, cash equivalents, and securities totaled $217.7 million, providing sufficient resources for strategic priorities [14] - The company has granted inducement equity awards to 9 individuals totaling 54,875 shares of restricted stock units and 49,750 options to purchase common stock [15][16]

Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline results expected in 2H2026Startup activities for CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks, on track; study is expected to initiate by YE2025Strong financial position with cash and cash equ ...

Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024 Company is reiterating revenue guidance for 2025 of $13 million and to achieve positive EBITDA during the year LANGHORNE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) ...

Second Quarter Results Strengthen Position as AI Leader in Roadway IntelligenceImproved Adjusted EBITDA: Substantially narrowed Adjusted EBITDA loss by $2 million for the six-month period.Operating Expense Reduction: Reduced operating expenses by 17% quarter over quarter and year over year, reflecting strong cost discipline.Quarterly Gross Revenue: Quarterly gross revenue of $12.4 million, showing the expected rebound from the prior quarter and resulting in revenue nearly flat year-over-year. ATM Offering h ...